The Translational Research in Ultrasound Theranostics (TRUST) lab brings together experts in material science, biomedical engineering and ultrasound imaging to design novel acoustically responsive materials to develop the next generation of ultrasound contrast agents. The TRUST program also works closely with clinical collaborators to build new tools to improve current quantitative ultrasound imaging techniques. Finally, the TRUST program is also at the forefront of image-guided drug delivery innovation as it developed a first in class ultrasound-guided drug delivery platform for the delivery of targeted therapies.
The TRUST lab is an interdisciplinary initiative at the intersection of material science, biomedical engineering, and ultrasound imaging, aiming to drive innovations with significant medical impact. By designing novel acoustically responsive materials, TRUST seeks to develop the next generation of ultrasound contrast agents, with the potential to enhance diagnostic precision and improve disease detection.
In collaboration with clinicians, TRUST is also dedicated to advancing quantitative ultrasound imaging techniques, striving to build tools that could enhance imaging accuracy and optimize clinical decision-making. Furthermore, the program is leading efforts in image-guided drug delivery innovation, having developed a first-in-class ultrasound-guided drug delivery platform. This technology holds promise for targeted therapy delivery, with the potential to improve treatment precision, minimize side effects, and maximize therapeutic efficacy.
By pushing the boundaries of ultrasound-based theranostics, TRUST aims to transform medical imaging and drug delivery, paving the way for future breakthroughs in personalized, non-invasive, and highly effective treatments for cancer, cardiovascular diseases, and other critical health conditions.